Objective To assess the rate of fetal loss following amniocentesis or chorionic villus sampling (CVS) in twin pregnancy. Methods MEDLINE, EMBASE and Cochrane databases were searched for studies reporting procedure-related complications following amniocentesis or CVS in twin pregnancy. The primary outcome was the rate of procedure-related fetal loss. The secondary outcomes were fetal loss occurring before 24 weeks of gestation and fetal loss occurring within 4 weeks after the procedure. Head-to-head meta-analyses were used to compare directly each outcome, between women undergoing amniocentesis and those not undergoing amniocentesis and between women undergoing CVS and those not undergoing CVS, and to compute pooled risk differences (RD) between women exposed and those not exposed to each invasive procedure. Additionally, meta-analyses of proportions were used to estimate the pooled rates of each of the three outcomes in women undergoing amniocentesis or CVS and in controls. Results Sixteen studies (3419 twin pregnancies undergoing and 2517 not undergoing an invasive procedure) were included. Head-to-head meta-analyses comparing directly twin pregnancies undergoing and those not undergoing amniocentesis showed a higher risk for overall fetal loss in those undergoing amniocentesis (odds ratio (OR), 1.46 (P = 0.04); RD, 0.013 (P = 0.04)), while there was no difference in the risk of either fetal loss before 24 weeks of gestation (OR, 1.59 (P = 0.06); RD, 0.010 (P = 0.11)) or fetal loss within 4 weeks after the procedure (OR, 1.38 (P = 0.3); RD, 0.003 (P = 0.8)). Overall, the pooled rate of fetal loss was 2.4% (95% CI, 1.4–3.6%) in twin pregnancies undergoing amniocentesis compared with 2.4% (95% CI, 0.9–4.6%) in those not undergoing amniocentesis. Head-to-head meta-analyses directly comparing twin pregnancies undergoing and those not undergoing CVS showed no significant difference in either overall fetal loss (OR, 1.61 (P = 0.5); RD, 0.003 (P = 0.8)) or fetal loss before 24 weeks of gestation (OR, 1.61 (P = 0.5); RD, 0.003 (P = 0.8)). Overall, the pooled rate of fetal loss was 2.0% (95% CI, 0.0–6.5%) in twin pregnancies undergoing CVS compared with 1.8% (95% CI, 0.3–4.2%) in those not undergoing CVS. Conclusion The risk of fetal loss following amniocentesis and CVS in twins is lower than reported previously and the rate of fetal loss before 24 weeks of gestation, or within 4 weeks after the procedure, did not differ from the background risk in twin pregnancy not undergoing invasive prenatal testing. These data can guide prenatal counseling for twin pregnancies undergoing invasive procedures. © 2020 International Society of Ultrasound in Obstetrics and Gynecology

Objectives: To assess the rate of fetal loss following amniocentesis and chorionic villous sampling (CVS) in twin pregnancies. Methods: Medline, Embase and Cochrane databases were searched for studies reporting procedure-related complications following amniocentesis or chorionic villous sampling in twin pregnancies. The primary outcome was the rate of procedure-related fetal loss. The secondary outcomes were fetal loss occurring before the 24th week of gestation and fetal loss occurring within 4 weeks after the procedure. Head-to-head meta-analyses were used to directly compare, for each outcome: (a) women undergoing amniocentesis versus women not undergoing amniocentesis, and (b) women undergoing CVS versus women not undergoing CVS, and to compute pooled risk differences between women exposed and not exposed to each invasive procedure. Additionally, meta-analyses of proportions were used to estimate the pooled rates of each of the three outcomes among women undergoing amniocentesis or CVS, and among controls, and head-to-head meta-analyses to directly compare, for each outcome: women undergoing amniocentesis versus women not undergoing amniocentesis; women undergoing CVS versus women not undergoing CVS. Results: Sixteen studies (3419 twin pregnancies undergoing and 2517 twin pregnancies not invasive procedures) were included. In twin pregnancies undergoing amniocentesis, head-to-head meta-analyses directly comparing women undergoing amniocentesis versus women not undergoing amniocentesis found a higher risk for overall fetal loss (OR 1.46, p=0.04; RD 0.013, p=0.04), while there was no difference when focusing on either fetal loss before 24 weeks of gestation (OR 1.59, p=0.06; RD 0.010, p=0.11) or fetal loss within 4 weeks from the procedure (OR 1.38, p=0.3; RD 0.003, p=0.8). In twin pregnancies undergoing CVS, head-to-head meta-analyses directly comparing women undergoing CVS versus women not undergoing CVS found no significant difference either when investigating overall fetal loss (OR 1.61, p=0.5; RD 0.003, p=0.8) or fetal loss before 24 weeks of gestation (OR 1.61, p=0.5; RD 0.003, p=0.8). Conclusion: The risk of fetal loss following amniocentesis and CVS in twins is lower than the one previously reported, and the rate of fetal loss before 24 weeks of gestation or within 4 weeks from the procedure did not differ from the background risk of a twin pregnancy not undergoing invasive prenatal testing. These data can guide prenatal counselling for twin pregnancies undergoing invasive procedures.

Risk of fetal loss following amniocentesis or chorionic villous sampling in twin pregnancies: a systematic review and meta‐analysis

Acuti Martellucci, C.;Flacco, M. E.
Formal Analysis
;
Manzoli, L.
Formal Analysis
;
D'Antonio, F.
2020

Abstract

Objectives: To assess the rate of fetal loss following amniocentesis and chorionic villous sampling (CVS) in twin pregnancies. Methods: Medline, Embase and Cochrane databases were searched for studies reporting procedure-related complications following amniocentesis or chorionic villous sampling in twin pregnancies. The primary outcome was the rate of procedure-related fetal loss. The secondary outcomes were fetal loss occurring before the 24th week of gestation and fetal loss occurring within 4 weeks after the procedure. Head-to-head meta-analyses were used to directly compare, for each outcome: (a) women undergoing amniocentesis versus women not undergoing amniocentesis, and (b) women undergoing CVS versus women not undergoing CVS, and to compute pooled risk differences between women exposed and not exposed to each invasive procedure. Additionally, meta-analyses of proportions were used to estimate the pooled rates of each of the three outcomes among women undergoing amniocentesis or CVS, and among controls, and head-to-head meta-analyses to directly compare, for each outcome: women undergoing amniocentesis versus women not undergoing amniocentesis; women undergoing CVS versus women not undergoing CVS. Results: Sixteen studies (3419 twin pregnancies undergoing and 2517 twin pregnancies not invasive procedures) were included. In twin pregnancies undergoing amniocentesis, head-to-head meta-analyses directly comparing women undergoing amniocentesis versus women not undergoing amniocentesis found a higher risk for overall fetal loss (OR 1.46, p=0.04; RD 0.013, p=0.04), while there was no difference when focusing on either fetal loss before 24 weeks of gestation (OR 1.59, p=0.06; RD 0.010, p=0.11) or fetal loss within 4 weeks from the procedure (OR 1.38, p=0.3; RD 0.003, p=0.8). In twin pregnancies undergoing CVS, head-to-head meta-analyses directly comparing women undergoing CVS versus women not undergoing CVS found no significant difference either when investigating overall fetal loss (OR 1.61, p=0.5; RD 0.003, p=0.8) or fetal loss before 24 weeks of gestation (OR 1.61, p=0.5; RD 0.003, p=0.8). Conclusion: The risk of fetal loss following amniocentesis and CVS in twins is lower than the one previously reported, and the rate of fetal loss before 24 weeks of gestation or within 4 weeks from the procedure did not differ from the background risk of a twin pregnancy not undergoing invasive prenatal testing. These data can guide prenatal counselling for twin pregnancies undergoing invasive procedures.
2020
Di Mascio, D.; Khalil, A.; Rizzo, G.; Buca, D.; Liberati, M.; Acuti Martellucci, C.; Flacco, M. E.; Manzoli, L.; D'Antonio, F.
File in questo prodotto:
File Dimensione Formato  
Manzoli L Ultrasound Obstet Gynecol 2020 (Risk of fetal loss).pdf

Open Access dal 07/07/2021

Descrizione: Accepted article
Tipologia: Post-print
Licenza: PUBBLICO - Pubblico con Copyright
Dimensione 1.53 MB
Formato Adobe PDF
1.53 MB Adobe PDF Visualizza/Apri
uog.22143.pdf

solo gestori archivio

Descrizione: Full text editoriale
Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 1.19 MB
Formato Adobe PDF
1.19 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2420804
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 49
  • ???jsp.display-item.citation.isi??? 44
social impact